4//SEC Filing
Huizinga Robert Bindert 4
Accession 0001628280-22-005118
CIK 0001600620other
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 4:10 PM ET
Size
11.0 KB
Accession
0001628280-22-005118
Insider Transaction Report
Form 4
Huizinga Robert Bindert
EVP of Research
Transactions
- Award
Common Stock
2022-03-02+8,500→ 74,228 total - Sale
Common Stock
2022-03-02$12.01/sh−4,849$58,236→ 69,379 total - Award
Restricted Stock Unit
2022-03-02+62,448→ 62,448 total→ Common Shares (62,448 underlying) - Award
Stock Option (right to buy)
2022-03-02+106,838→ 106,838 totalExercise: $12.01Exp: 2032-03-02→ Common Stock (106,838 underlying)
Footnotes (4)
- [F1]On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration.
- [F2]Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards.
- [F3]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date.
- [F4]One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.
Documents
Issuer
Aurinia Pharmaceuticals Inc.
CIK 0001600620
Entity typeother
Related Parties
1- filerCIK 0001837648
Filing Metadata
- Form type
- 4
- Filed
- Mar 3, 7:00 PM ET
- Accepted
- Mar 4, 4:10 PM ET
- Size
- 11.0 KB